Doxazosin, an α1-adrenergic antihypertensive agent, decreases serum oxidized LDL

American Journal of Hypertension

Volumn 14, Issue 3, 2001, Pages 267-270

  Kinoshita, Makoto ^a   Shimazu, Nobuko ^a   Fujita, Mineko ^a   Fujimaki, Yuko ^a   Kojima, Kyoko ^a   Mikuni, Yoko ^a   Horie, Eiko ^a   Teramoto, Tamio ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Doxazosin; Oxidized low density lipoprotein

Indexed keywords

ANTIHYPERTENSIVE AGENT; DOXAZOSIN; OXIDIZED LOW DENSITY LIPOPROTEIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INHIBITION; FEMALE; HUMAN; LIPID BLOOD LEVEL; MALE; OXIDATION; PRIORITY JOURNAL; BLOOD; OXIDATION REDUCTION REACTION;

ADRENERGIC ALPHA-ANTAGONISTS; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; DOXAZOSIN; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; OXIDATION-REDUCTION;

EID: 0034745320     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(00)01263-2     Document Type: Article

References (29)

1. Low density lipoprotein oxidation and its pathobiological significance
2. Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs
3. Mechanism of uptake of copper-oxidized low density lipoprotein in macrophages is dependent on its extent of oxidation
4. Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low density lipoprotein
5. Oxidized low-density lipoprotein is chemotactic for arterial smooth muscle cells in culture
6. Phosphatidylinositol 3-kinase is involved in the induction of macrophage growth by oxidized low density lipoprotein
7. Role of oxidized human plasma low density lipoproteins in atherosclerosis: Effects on smooth muscle cell proliferation
8. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions
9. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: Recognition by receptors for acetylated low density lipoproteins
10. The pathogenesis of coronary artery disease and the acute coronary syndromes (1)
11. The pathogenesis of coronary artery disease and the acute coronary syndromes (2)
12. In vivo catabolism of biologically modified LDL
13. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma
14. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum
15. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody
16. Simple and practical sandwich-type enzyme immunoassay for human oxidatively modified low density lipoprotein using anti-oxidized phosphatidylcholine monoclonal antibody and anti-human apolipoprotein-B antibody
17. Inhibition of low density lipoprotein oxidation in vitro by the 6- and 7-hydroxy-metabolites of doxazosin, an alpha 1-adrenergic antihypertensive agent
18. Oxidized phosphatidylcholines that modify proteins. Analysis by monoclonal antibody against oxidized low density lipoprotein
19. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides
20. Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender, presence of white coat hypertension. Results of the HALT Study
21. Changes of nocturnal blood pressure dipping status in hypertensives by nighttime dosing of alpha-adrenergic blocker, doxazosin: Results from the HALT study
22. Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow
23. Long-term effects of doxazosin, an alpha 1-blocker, on serum lipids in hypertensive patients
24. Estimation of plasma low density lipoprotein cholesterol concentration without use of the preparative ultracentrifuge
25. Supplementation with vitamin E but not beta-carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro. Effect of cigarette smoking
26. Effect of dietary supplementation with alphatocopherol on the oxidative modification of low density lipoprotein
27. Probucol inhibits oxidative modification of low density lipoprotein
28. Effects of d-alpha-tocopherol supplementation on experimentally induced primate atherosclerosis
29. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia